CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Peanut oral immunotherapydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00932828
NCT00932828Phase 2Completed
CompareCT.gov

Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study; Grant "Optimizing Tolerance Induction in Peanut Allergy: The DEVIL Study"

University of North Carolina, Chapel Hill·interventional·Posted Jul 3, 2009·Updated May 24, 2018

In Brief

A Phase 2 clinical trial evaluating Peanut oral immunotherapy for Food Hypersensitivity. Completed, enrolled 37 participants across 1 site.

Detailed Summary

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Hypersensitivity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 3, 2009
Enrollment StartJun 22, 2009
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 17.0 years ago

Interventions

Peanut oral immunotherapydrug

Defatted peanut in flour form to be used as treatment for peanut allergy